Kamada (KMDA) Upgraded at ValuEngine

Kamada (NASDAQ:KMDA) was upgraded by stock analysts at ValuEngine from a “sell” rating to a “hold” rating in a note issued to investors on Friday.

A number of other brokerages have also commented on KMDA. Zacks Investment Research raised Kamada from a “sell” rating to a “hold” rating in a report on Wednesday, October 25th. Jefferies Group reissued a “buy” rating and set a $7.00 price objective on shares of Kamada in a report on Thursday, October 12th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $8.50.

Shares of Kamada (NASDAQ KMDA) traded down $0.05 on Friday, reaching $5.20. The company’s stock had a trading volume of 21,986 shares, compared to its average volume of 24,201. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.71 and a quick ratio of 2.73. The company has a market cap of $211.73, a price-to-earnings ratio of -129.97 and a beta of 1.04. Kamada has a 1 year low of $3.75 and a 1 year high of $8.61.

Several hedge funds have recently added to or reduced their stakes in KMDA. Nexthera Capital LP bought a new position in shares of Kamada in the second quarter valued at approximately $1,805,000. Paulson & CO. Inc. grew its holdings in shares of Kamada by 8.2% in the second quarter. Paulson & CO. Inc. now owns 790,800 shares of the biotechnology company’s stock valued at $4,745,000 after acquiring an additional 60,000 shares in the last quarter. Worth Venture Partners LLC bought a new position in shares of Kamada in the third quarter valued at approximately $246,000. Navellier & Associates Inc bought a new position in shares of Kamada in the second quarter valued at approximately $303,000. Finally, Analyst IMS Investment Management Services Ltd. grew its holdings in shares of Kamada by 125.5% in the third quarter. Analyst IMS Investment Management Services Ltd. now owns 89,843 shares of the biotechnology company’s stock valued at $431,000 after acquiring an additional 50,000 shares in the last quarter. 6.31% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This article was originally reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://www.chaffeybreeze.com/2018/01/05/kamada-kmda-upgraded-at-valuengine.html.

Kamada Company Profile

Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.

Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply